Skip to main content

Table 5 Disutility

From: Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States

Parameters name

Base

Range

Source

China

   

Fatigue

 − 0.029

 − 0.036 to  − 0.022

[1]

Anemia

 − 0.074

 − 0.11 to  − 0.037

[15]

Neutropenia

 − 0.09

 − 0.12 to  − 0.059

[15]

The US

   

Fatigue

 − 0.29

 − 0.348 to  − 0.232

[13]

Anemia

 − 0.12

 − 0.144 to  − 0.096

[13]

Neutropenia

 − 0.09

 − 0.108 to  − 0.072

[13]

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us